Skip to main content

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

Journal of Neurology volume 261, pages 773–783 (2014)Cite this article

Abstract

The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and descriptively compared laquinimod with interferon beta (IFNβ)-1a (Avonex® reference arm). RRMS patients age 18–55 years with Expanded Disability Status Scale (EDSS) scores of 0–5.5 and documented pre-study relapse (≥ 1 in previous year, 2 in previous 2 years, or 1 in previous 1–2 years and ≥ 1 GdE lesion in the previous year) were randomized (1:1:1) to laquinimod 0.6 mg once-daily, matching oral placebo, or IFNβ-1a IM 30 μg once-weekly (rater-blinded design), for 24 months. The primary endpoint was annualized relapse rate (ARR); secondary endpoints included percent brain volume change (PBVC) and 3-month confirmed disability worsening. In all, 1,331 patients were randomized: laquinimod (n = 434), placebo (n = 450), and IFNβ-1a (n = 447). ARR was not significantly reduced with laquinimod [−18 %, risk ratio (RR) = 0.82, 95 % CI 0.66–1.02; p = 0.075] vs. placebo. Laquinimod significantly reduced PBVC (28 %, p < 0.001). Confirmed disability worsening was infrequent (10 % laquinimod, 13 % placebo). The change in confirmed disability worsening with laquinimod measured using EDSS was −31 % [hazard ratio (HR) 0.69, p = 0.063], and using Multiple Sclerosis Functional Composite (MSFC) z-score was −77 % (p = 0.150), vs. placebo. IFNβ-1a reduced ARR 26 % (RR = 0.74, 95 % CI 0.60–0.92, p = 0.007), showed no effect on PBVC loss (+11 %, p = 0.14), and changes in disability worsening were −26 and −66 % as measured using the EDSS (HR 0.742, p = 0.13) and MSFC (p = 0.208), respectively. Adverse events occurred in 75, 82, and 70 % of laquinimod, IFNβ-1a, and placebo patients, respectively. Once-daily oral laquinimod 0.6 mg resulted in statistically nonsignificant reductions in ARR and disability progression, but significant reductions in brain atrophy vs. placebo. Laquinimod was well-tolerated.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Avonex® (interferon beta-1a) prescribing information (2013) Biogen Idec, Inc, Cambridge, MA, USA. Rev 03/2013

  2. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M (2006) Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 129:2620–2627

    Article  PubMed  Google Scholar 

  3. Bruck W, Pfortner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, Hanisch UK, Regen T, van Rossum D, Brakelmann L, Hagemeier K, Kuhlmann T, Stadelmann C, John GR, Kramann N, Wegner C (2012) Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 124:411–424

    Article  PubMed Central  PubMed  Google Scholar 

  4. Bruck W, Wegner C (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306:173–179

    Article  CAS  PubMed  Google Scholar 

  5. Cohen BA, Rieckmann P (2007) Emerging oral therapies for multiple sclerosis. Int J Clin Pract 61:1922–1930

    Article  CAS  PubMed  Google Scholar 

  6. Cohen JA, Reingold SC, Polman CH, Wolinsky JS (2012) Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 11:467–476

    Article  PubMed  Google Scholar 

  7. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca M, Filippi M, ALLEGRO Study Group (2012) Placebo-controlled trial of oral laquinimod in multiple sclerosis. N Engl J Med 366:1000–1009

    Article  CAS  PubMed  Google Scholar 

  8. Comi G, Obramsky O, Arbizu T, Boyko AN, Gold R, Havrdova E, Komoly S, Mesaros S, Selmaj K, Sharrack B, Filippi M (2009) Long-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favourable safety and sustained low relapse rate and MRI activity. Mult Scler 15(suppl2):S127. Abstract P443

  9. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371:2085–2092

    Article  CAS  PubMed  Google Scholar 

  10. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122(Pt 5):871–882

    Article  PubMed  Google Scholar 

  11. European Medicines Agency-Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. London

  12. Fisher E, Lee JC, Nakamura K, Rudick RA (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64:255–265

    Article  PubMed  Google Scholar 

  13. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097

    Google Scholar 

  14. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098–1107

    Google Scholar 

  15. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE III, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 39:285–294

    Article  CAS  PubMed  Google Scholar 

  16. Johnson KP (2010) Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag 6:153–172

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401

    Google Scholar 

  18. Kieseier BC (2011) The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 25:491–502

    Article  CAS  PubMed  Google Scholar 

  19. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    Article  CAS  PubMed  Google Scholar 

  20. Mishra MK, Wang J, Silva C, Mack M, Yong VW (2012) Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol 181:642–651

    Article  CAS  PubMed  Google Scholar 

  21. O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, O’Connor P, Filippi M, Arnason B, Cook S, Goodin D, Harung HP, Kappos L, Jeffery D, Comi G (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889–897

    Article  PubMed  Google Scholar 

  22. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293–1303

    Google Scholar 

  23. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64:987–991

    Article  CAS  PubMed  Google Scholar 

  24. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846

    Article  PubMed  Google Scholar 

  25. Popescu BF, Lucchinetti CF (2012) Pathology of demyelinating diseases. Annu Rev Pathol 7:185–217

    Article  CAS  PubMed  Google Scholar 

  26. Reuben A (2004) Hy’s law. Hepatology 39:574–578

    Article  PubMed  Google Scholar 

  27. Rudick RAM, Fisher EP, Lee J-CM, Simon JMP, Jacobs LM, the Multiple Sclerosis Collaborative Research Group (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53:1698–1704

    Article  CAS  PubMed  Google Scholar 

  28. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS (2012) Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 7:e33797

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Thone J, Gold R (2011) Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol 7:365–370

    Article  CAS  PubMed  Google Scholar 

  30. Wegner C, Stadelmann C, Pfortner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Bruck W (2010) Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227:133–143

    Article  CAS  PubMed  Google Scholar 

  31. Wei L, Zhang J (2001) Analysis of data with imbalance in the baseline outcome variable for randomized clinical trials. Drug Inf J 35:1201–1214

    Google Scholar 

  32. Whitaker JN, McFarland HF, Rudge P, Reingold SC (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1:37–47

    CAS  PubMed  Google Scholar 

  33. Zipp F, Aktas O (2006) The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29:518–527

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the Independent Data Monitoring Committee, the staff of NeuroRx Research, the MRI Analysis Center, and the Principal Investigators for each country; Yulia Sidi, M.A. of the Teva Statistical Data Management Team (Netanya, Israel) managed the statistical analyses; Pippa Loupe, Ph.D. of Medical Affairs, Teva Pharmaceuticals (Kansas City, MO), and two independent medical writers, paid by the sponsor, James D. Bergstrom, Ph.D. of Mountain Stream Communications, LLC (Hillsborough, NJ), and Sheila Truten, B.S. of Medical Communication Company (Wynnewood, PA) collaborated with the authors on the first draft of the paper, copyedited the manuscript and prepared figures and tables.

Supported by Teva Pharmaceutical Industries, Ltd., Petach Tikva, Israel.

Conflicts of interest

TL Vollmer has received consulting fees, and his institution has received a grant and consulting fee for his participation in the BRAVO study; he is a board member of Rocky Mountain MS Center; his institution has received consultancy fees from Biogen Idec, Teva, Elan, Hoffman-LaRoche, Accelerated Cure Project, Genzyme, Bristol-Myers Squibb, Acorda, Novartis, Questor, Medscape, Xenoport, and Sanofi; his institution received fees for expert testimony from Ham VS Bennett and Wagner VS Strand; his institution received grants/grants pending from Teva, Biogen Idec, Genzyme, Ono, Eli Lilly, Novartis, BioMS, Orasi, Sanofi-Aventis, NIH, EMD Sorono, Acorda, Accelerated Cure Project, Hoffmann-LaRoche, Jensen Research, Daiichi Sankyo, Elan, Janssen Pharmaceutical, Avanir Pharmaceutical, MedImmune, Delta Quest, Biosite Inc., University of Alabama, and Genentech.

PS Sorensen has received payment as co-principal investigator and for travel support for the BRAVO study from Teva; he has received consultancy fees from Merck Serono, Teva, Novartis, Sanofi-Aventis, and Biogen Idec; his institution has received research support grants/grants pending from Biogen Idec, Novartis, and Sanofi-Aventis; and he is on the speaker’s bureau of Merck Serono, Novartis, Bayer Schering, Teva, Sanofi-Aventis, Biogen Idec, and Genzyme.

K Selmaj has received compensation for consulting and speaking from Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, and Teva.

F Zipp’s institution received a grant from Teva for participation in BRAVO and has received grants/grants pending from Novartis and Merck Serono; she has received fees for consultancy with Merck-Serono, Ono, Sanofi-Aventis, and Biogen; she is a board member of Octapharma; and serves on the speaker’s bureau of Novartis, Merck-Serono, Biogen, Genzyme, and Sanofi-Aventis.

E Havrdova’s institution received funding for clinical trial participation, she has received compensation for consultancy from Biogen Idec, Genzyme, Merck Serono, and Novartis; serves on the speaker’s bureaus of Biogen Idec, Merck Serono, Novartis, and Teva; her institution has received a grant/grant pending from Biogen Idec.

JA Cohen received, in the previous 2 years, compensation for consulting from Teva and Vaccinex; his institution received research support from Biogen Idec, Novartis, Receptos, Synthon, Teva, US Department of Defense, National Institutes of Health, and National MS Society.

N Sasson is employed by Teva; owns stock in and receives travel/meeting expenses from Teva.

Y Gilgun-Sherki is employed by Teva; owns stock in and receives travel/meeting expenses from Teva; and is a co-holder of patents with Teva.

D Arnold has received fees for consulting, travel support, and research related to the BRAVO study; has received consultancy fees from Biogen Idec, EMD Serono, Genentech, Glaxo Smith Kline, Merck Serono, Mitsubishi, Novartis, and Roche; his institution has received grants/grants pending from Bayer Healthcare, CIHR, and MSSC and owns US patent No. 6,347,239.

Author information

Authors and Affiliations

  1. Department of Neurology, University of Colorado, Aurora, CO, USA

    T. L. Vollmer

  2. Danish Multiple Sclerosis Center, University of Copenhagen, Copenhagen, Denmark

    P. S. Sorensen

  3. Department of Neurology, Rigshospitalet, Copenhagen, Denmark

    P. S. Sorensen

  4. Department of Neurology, Medical University of Łódź, Lodz, Poland

    K. Selmaj

  5. Department of Neurology, Rhine Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

    F. Zipp

  6. First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

    E. Havrdova

  7. The Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

    J. A. Cohen

  8. Teva Statistical Data Management Team, Teva Pharmaceuticals, Netanya, Israel

    N. Sasson

  9. Teva Innovative Research and Development, Teva Pharmaceuticals, Netanya, Israel

    Y. Gilgun-Sherki

  10. McGill University, Montreal, QC, Canada

    D. L. Arnold

  11. NeuroRx Research, Montreal, QC, Canada

    D. L. Arnold

  12. Rocky Mountain MS Center, Rocky Mountain MS Clinic, Anschutz Medical Center, University of Colorado, Denver, RM L15-5511, A01, Mail stop B185, 12631 E 17th Avenue, Aurora, CO, 80045, USA

    T. L. Vollmer

Authors
  1. T. L. Vollmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. S. Sorensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Selmaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Zipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Havrdova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. A. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Sasson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Gilgun-Sherki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. L. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the BRAVO Study Group

Corresponding author

Correspondence to T. L. Vollmer.

Additional information

T. L. Vollmer and P. S. Sorensen were co-principal investigators for the BRAVO trial, contributed equally to the manuscript, and should be considered equal lead authors on this publication.

N. Sasson of Teva Pharmaceutical Industries provided statistical support for the manuscript.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 36 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vollmer, T.L., Sorensen, P.S., Selmaj, K. et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261, 773–783 (2014). https://doi.org/10.1007/s00415-014-7264-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-014-7264-4

Keywords

  • Laquinimod
  • Multiple sclerosis
  • Disability
  • EDSS
  • Interferon beta-1a